Department of Radiotherapy, Chair of Oncology, Medical University of Lodz, Poland ; Department of Radiotherapy, Regional Cancer Center, Copernicus Memorial Hospital of Lodz, Poland.
Arch Med Sci. 2013 Feb 21;9(1):79-85. doi: 10.5114/aoms.2013.33066. Epub 2013 Feb 18.
There is a need to assess the value of the novel potentially useful biomarkers in ovarian tumors. The aim of study was to assess the value of sAgNOR analysis in ovarian serous epithelial tumors.
The analysis was performed in ovaries from 113 patients treated operatively due to serous ovarian tumors (30 adenomas, 14 borderline tumors and 69 cancers). After silver staining of paraffin specimens from surgery, sAgNOR in tumor cells was analyzed. Additionally, the value of the argyrophilic nucleolar organizer region area/nucleus ratio (sAgNOR) in the prediction of disease-free survival (DFS) and overall survival (OS) in 52 patients with serous ovarian cancer with complete follow-ups in November 2009 was evaluated. Age, grading, radicality of surgery and FIGO staging were analyzed as additional factors.
SAGNOR IN ADENOMAS, BORDERLINE TUMORS AND CANCERS WAS IN THE FOLLOWING RANGES: (0.73 ±0.23) × 10(6), (0.81 ±0.18) × 10(6) and (0.96 ±0.33) × 10(6) [AgNOR/cm(2)] respectively. In cancers from G1 to G3 sAgNOR was (1.02 ±0.32) × 10(6) (G1), (0.98 ±0.37) × 10(6) (G2) and (0.82 ±0.24) × 10(6) (G3) [AgNOR/cm(2)] respectively. In univariate analysis, but not in multivariate analysis, staging negatively correlated with better DFS and OS. sAgNOR, age of patients, grading and radicality of surgery were not associated with DFS or OS in either univariate or multivariate analysis.
sAgNOR analysis is not sufficient to precisely characterize cellular kinetics in serous ovarian tumors, and the analysis of sAgNOR, mAgNOR and pAgNOR should be performed commonly. The prognostic significance of sAgNOR in patients with serous ovarian cancer was not proven.
需要评估新型潜在有用生物标志物在卵巢肿瘤中的价值。本研究旨在评估 sAgNOR 分析在卵巢浆液性上皮性肿瘤中的价值。
对因浆液性卵巢肿瘤（30 例腺瘤、14 例交界性肿瘤和 69 例癌）而行手术治疗的 113 例患者的卵巢进行分析。对手术石蜡标本进行银染色后，分析肿瘤细胞中的 sAgNOR。此外，还评估了在 2009 年 11 月完全随访的 52 例浆液性卵巢癌患者中，sAgNOR（银染核仁组成区相关嗜银蛋白）在预测无病生存率（DFS）和总生存率（OS）方面的价值，并分析了年龄、分级、手术根治性和 FIGO 分期等附加因素。
腺瘤、交界性肿瘤和癌症中的 SAGNOR 分别为：（0.73 ±0.23）×10(6)、（0.81 ±0.18）×10(6)和（0.96 ±0.33）×10(6)[AgNOR/cm(2)]。G1 到 G3 的癌症中 sAgNOR 分别为（1.02 ±0.32）×10(6)（G1）、（0.98 ±0.37）×10(6)（G2）和（0.82 ±0.24）×10(6)（G3）[AgNOR/cm(2)]。在单因素分析中，但不是在多因素分析中，分期与更好的 DFS 和 OS 呈负相关。sAgNOR、患者年龄、分级和手术根治性在单因素或多因素分析中均与 DFS 或 OS 无关。
sAgNOR 分析不足以精确描述浆液性卵巢肿瘤中的细胞动力学，应共同进行 sAgNOR、mAgNOR 和 pAgNOR 分析。sAgNOR 在浆液性卵巢癌患者中的预后意义尚未得到证实。
